Literature DB >> 1883008

Plasma homovanillic acid in schizotypal personality disorder.

L J Siever1, F Amin, E F Coccaro, D Bernstein, R J Kavoussi, O Kalus, T B Horvath, P Warne, M Davidson, K L Davis.   

Abstract

Schizotypal patients were found to have a significantly higher mean plasma HVA concentration than normal comparison subjects. Furthermore, plasma HVA concentration positively correlated with "psychotic-like" schizotypal symptoms. These results implicate dopaminergic mechanisms modulating the psychotic-like symptoms of schizotypal personality disorder.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1883008     DOI： 10.1176/ajp.148.9.1246

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  7 in total

Review 1.  The brain in schizotypal personality disorder: a review of structural MRI and CT findings.

Authors:  Chandlee C Dickey; Robert W McCarley; Martha E Shenton
Journal:  Harv Rev Psychiatry       Date:  2002 Jan-Feb       Impact factor: 3.732

Review 2.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

3.  Factors in sensory processing of prosody in schizotypal personality disorder: an fMRI experiment.

Authors:  Chandlee C Dickey; Istvan A Morocz; Daniel Minney; Margaret A Niznikiewicz; Martina M Voglmaier; Lawrence P Panych; Usman Khan; Rayna Zacks; Douglas P Terry; Martha E Shenton; Robert W McCarley
Journal:  Schizophr Res       Date:  2010-04-01       Impact factor: 4.939

4.  Levodopa reverses gait asymmetries related to anhedonia and magical ideation.

Authors:  Christine Mohr; Theodor Landis; H Stefan Bracha; Marc Fathi; Peter Brugger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

5.  Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.

Authors:  Tomiki Sumiyoshi; A Roy; C-H Kim; K Jayathilake; M A Lee; C Sumiyoshi; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

6.  Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.

Authors:  Oliver D Howes; Subrata K Bose; Federico Turkheimer; Isabel Valli; Alice Egerton; Lucia R Valmaggia; Robin M Murray; Philip McGuire
Journal:  Am J Psychiatry       Date:  2011-07-18       Impact factor: 18.112

Review 7.  Theranostic Biomarkers for Schizophrenia.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Dubravka Svob Strac; Suzana Uzun; Oliver Kozumplik; Nela Pivac
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.